Volume 59 - Issue 5 - May 2013
A Cross-sectional, Comparative Study of Pain and Activity in Persons With and Without Injection-Related Venous Ulcers
- 5/10/2013
- 0 Comments
- 356 reads
Index: Ostomy Wound Manage. 2013;59(5):14–24.
Abstract
Persons with leg ulcers, including venous ulcers, often report pain. A cross-sectional, comparative study was conducted among 61 patients receiving care in an urban clinic (31 with and 30 without a venous ulcer, mean age 54 years [range 40 to 65 years], 93% African American) to examine pain and its relation to activity and walking in persons with injection-related venous ulcers. The questionnaire included items about pain and its treatment, as well as activity and walking (ie, Brief Pain Inventory [BPI] Short Form, Self-Treatment of Pain, Pain and Narcotic Use, Difficulty with Activities, and Walking Scale questionnaires). Among those with a venous ulcer (VU+), worst pain significantly related to total interference (r = 0.65, P <0.0001) and total difficulty (r = 0.42, P = 0.02) BPI scores. The common pain sites for those VU+ involved the legs (24, 36.4%), wound sites (13, 19.7%), back (eight, 12.1%), general body (five, 7.6%), shoulder and knee (four, 6.1% each), and other (eight, 12.1%). Persons VU+ were more likely than those without a venous ulcer (VU-) to have received a prescription for narcotics in the past year (96% versus 41%, X2 = 21.3, P <0.0001). Persons VU+ versus VU- were significantly (X2 = 8.89, P = 0.003) more likely to resort to street drug use and relapse to addiction if pain was not adequately treated. They were also twice as likely to have decreased walking over the past 5 years (67% versus 33%, X2 = 5.93, P <0.02). Among those VU+, venous ulcers added to chronic pain and decreased walking. These findings highlight the negative effects of injection-related venous ulcers on pain, activity, and walking, as well as the propensity of this group to resort to illicit drug use for pain control. Persons VU+ should have pain assessed and treated.
Keywords: venous ulcers, intravenous substance abuse, complication, pain, activity
Ramadan Fasting in Patients with a Stoma: A Prospective Study of Quality of Life and Nutritional Status
- 5/10/2013
- 0 Comments
- 248 reads
Index: Ostomy Wound Manage. 2013;59(5):26–32.
Abstract
Ramadan fasting is an Islamic obligation for healthy Muslims after the age of puberty. Persons with an acute or chronic disease may be excused from this obligation; the degree of the disease is an important parameter for not fasting. Little is known about the effect of fasting on persons with a stoma. A prospective study was conducted among 56 patients with a cancer-related fecal stoma (33 [58.9%] male, mean age 55.9 ± 13.1 years) over two periods of Ramadan to analyze the effect of fasting 15 to 16 hours on nutritional and metabolic status and quality of life. Eligible patients were divided into two groups: fasting (n = 14) and nonfasting (n = 42). Demographic and stoma information, as well as disease and treatment-related variables, were evaluated. Participants completed cancer patient and colorectal cancer patient quality-of-life instruments and rated their religious orientation. Laboratory tests (blood urea nitrogen, creatinin, cholesterol, prealbumin, albumin, and transferrin) were performed 1 to 3 weeks before Ramadan, and questionnaires and tests were repeated 1 to 3 weeks after Ramadan in people who fasted. Demographic parameters, including religious orientation scale scores, were similar between fasting and nonfasting groups. Patients in the fasting group had significantly higher albumin levels (4.6 ± 0.2 versus 4.1 ± 0.4, P = 0.001), prealbumin levels (27.6 ± 7.4 versus 21.3 ± 8.5, P = 0.018), and global health status scores (81.5 ± 16.7 versus 68.3 ± 20.1, P = 0.030) than patients in the nonfasting group. Patients who fasted also had their stoma for a longer period of time than patients in the nonfasting group (average 9 months [range 3–87 months] in the fasting versus 4.5 months [range 3–36 months] in the nonfasting group, P = 0.084), and the proportion of patients with a permanent stoma was higher in the fasting group than in the nonfasting group (P = 0.051). Ramadan fasting had almost no influence on quality of life. Fasting lowered prealbumin levels (27.6 ± 7.4 versus 21.2 ± 4.4; P = 0.046), but did not adversely affect other nutritional or global health status variables. Most patients in the fasting group (13, 92.9%) stated they would feel sad if they were not fasting. The results of this study suggest that although fasting may decrease prealbumin levels, persons with a stoma and good nutritional status may decide for themselves whether to fast.
Keywords: prospective study, surgical stoma, fasting, Islam, nutritional status
The Effect of a Cellulose Dressing and Topical Vancomycin on Methicillin-resistant Staphylococcus aureus (MRSA) and Gram-positive Organisms in Chronic Wounds: A Case Series
- 5/10/2013
- 0 Comments
- 516 reads
Index: Ostomy Wound Manage. 2013;59(5):34–43.
Abstract
High levels of persistent bacteria may contribute to wound chronicity and delayed healing. A prospective study was conducted to: 1) evaluate the effect of applying vancomycin topically on appropriately cultured chronic lower leg wounds, specifically methicillin-resistant Staphylococcus aureus (MRSA) and Gram-positive bacteria, and 2) evaluate its effect in combination with a cellulose dressing on healing. Twenty-three (23) outpatients (11 men, 12 women, average age 65 years [range 39–89 years]) with lower extremity wounds (15 venous ulcers, six chronic open wounds with a history of diabetes, and two chronic open trauma wounds) averaging 43.58 weeks’ (range 5–121 weeks) duration and swab-cultured positive for MRSA or Gram-positive bacteria were provided 1 g vancomycin delivered by a cellulose dressing and changed every 72 hours. Patients served as their own control, and all wounds were debrided once a week. Wound surface area and bacterial and exudate levels were recorded weekly during the 3-week pretreatment period and compared to 3-week treatment period levels. Patients were followed until healed. Mean change in wound surface area was +14.5% (SD 71.91) per week before and -24.6% (SD 13.59) during the vancomycin treatment period (P = 0.014), average exudate levels decreased from 2.75 (range 1–4) to 1.81 (range 0–3) (P = 0.016), and the number of patients with positive wound cultures for MRSA or Gram-positive bacteria decreased from 23 to four after the 3-week study period. All wounds healed after an average of 8.18 weeks (SD 4.76, range 2–17 weeks). The results of this study suggest topical vancomycin applied using a dressing that retains moisture reduces wound bacterial load and may facilitate healing. Randomized, controlled clinical studies to evaluate the effectiveness and efficacy of this treatment modality and explore the relationship between wound culture results and healing are warranted.
Keywords: leg ulcers, case study, methicillin-resistant Staphylococcus aureus, vancomycin, wound healing
Editor’s Opinion: Giving Sizeable Coverage to Billing Issues
- 5/10/2013
- 0 Comments
- 107 reads
Not unlike scientific research, investigative journalism takes time, perseverance, and pursuit of the evidence. While pressure to follow a 24-hour news cycle and the number of ways to access that information has grown, the size of the medium we use to read about it — and our time to do so — has shrunken, literally, to pocket-size. Emphasis on the short story that fits on a small screen has increased, leaving readers with the mistaken impression they know the whole story.
The real story and a real understanding of complex problems or research require much more screen (and print) space and much more time to tell and read. OWM readers are accustomed to (and deserve to be presented) the fullest picture possible on any topic we cover. Original research reports are never truncated for the sake of time or space because doing so would greatly reduce the value of the work and negatively affect its potential contribution to future studies. In the nonscientific press, however, the short story reigns supreme.
Special to OWM: The Seed Remains: A Tribute to Linda King Aukett (1943–2013)
- 5/10/2013
- 0 Comments
- 72 reads
Oh heart, if one should say to you that the soul perishes like the body, answer that the flower withers, but the seed remains. — Kahlil Gibran
Linda and Ken. The Auketts. The global champions for people living with an ostomy. Tireless crusaders on nearly every continent on the planet. Ken and Linda. The heart and soul of the United Ostomy Association (UOA), International Ostomy Association (IOA), and United Ostomy Association of America (UOAA). The intrepid duo has been tragically reduced by one. Linda, Ken’s beautiful, statuesque, raven-haired love, has been taken too quickly from us all. Her flower has withered, but the seeds she planted will take root and blossom once again.
Continence Coach: Pelvic Floor Pain Syndrome in Chronic Pelvic Pain Revisited: A Case Study
- 5/10/2013
- 0 Comments
- 150 reads
In the February 2013 “Continence Coach,” Nancy Muller discussed pelvic floor pain syndrome in chronic pelvic pain (CPP).1 Pelvic muscle pain has several aliases and implies a pain source from the myofascial structures of the pelvis that sometimes goes undiagnosed. It can exist alone with no concomitant medical pathology or as either a precursor or sequela to urological, gynecological, and colorectal medical conditions or other musculo-skeletal-neural issues.2 Due to the phenomenon of somatovisceral convergence, primary pain generators can be elusive. Pathology in the viscera can refer pain and symptoms to somatic structures and vice versa.3 It is also well documented that chronic neuropathic and musculoskeletal pain are related to abnormal restructuring of the body’s somatosensory and motor cortices, as well as other areas of the brain.4 This makes treating the CPP patient more challenging, because clinicians must acknowledge the brain’s role in chronic pain.
The following is a case in point. The patient’s complex symptom presentation included both visceral and somatic dysfunction, a highly sensitive nervous system, and biopsychosocial factors that needed to be addressed over the course of her treatment. As the research5 suggests, a team approach was necessary for a successful outcome.
My Scope of Practice: Evolution of an Ostomy Clinic
- 5/10/2013
- 0 Comments
- 149 reads
This month, Ostomy Wound Management highlights the scope of practice of an ostomy clinic and the individuals dedicated to providing quality care to a previously underserved community.
Patients must have access to an ostomy nurse specialist when facing a fecal or urinary diversion. Preoperative visits for educational and stoma site marking, postsurgical visits for follow-up maintenance, and ongoing need to address pouching concerns are essential for a patient’s successful adaptation to life with a hole in his/her abdomen. A 2007 proposal to the Duke Raleigh Hospital (Raleigh, NC) Nurse Executive Board and Finance Committee resulted in development of a clinic that continues to grow and enhance the care of persons with ostomies in Raleigh/Durham and the surrounding communities.
AAWC Update
- 5/10/2013
- 0 Comments
- 34 reads
2013 AAWC Board of Directors election results
The AAWC thanks members of its Board of Directors and congratulates those newly elected or re-elected. These newly elected board members will serve a 2-year term from 2013–2015. All board members attended the Annual Board Meeting on May 1 and officially took office on May 3 at the Annual AAWC Membership Meeting held during SAWC Spring in Denver, CO.
New Products and Industry News
- 5/10/2013
- 0 Comments
- 84 reads
Five products introduced in Singapore and Malaysia
Oculus Innovative Sciences, Inc’s (Petaluma, CA) partner, Dyamed Biotech Pte. Ltd, is initiating rollout of five new Microcyn® Technology-based products in Singapore and Malaysia, both in the hospital and consumer markets. The five products, which include Dermacyn™ BabyGuard, Dermacyn DermaGuard, Dermacyn SkinGuard Solution, Dermacyn SkinGuard Hydrogel, and Dermacyn Wound Care Hydrogel, will be rolled out sequentially with all products commercialized by year’s end.
For more information, visit www.oculusis.com.




